Glenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated March 19, 2026, titled "Glenmark Pharmaceuticals Inc., USA launches Authorized Generic to Milnacipran Hydrochloride Tablets, 12.5 mg, 25 mg, 50 mg, and 100 mg".
GLENMARK · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Glenmark's US subsidiary has launched an authorized generic of Milnacipran Hydrochloride Tablets in four strengths: 12.5 mg, 25 mg, 50 mg, and 100 mg. It is the authorized generic of Savella® Tablets, a branded product used for a specific approved indication. According to IQVIA data for the 12 months ending January 2026, the Savella® market in the US generated annual sales of about $102.9 million. Marc Kikuchi, President & Business Head, North America, said the launch reflects Glenmark's commitment to providing affordable treatment options. The product will be sold only for indications listed in Glenmark's approved label.
This gives Glenmark a foothold in a roughly $103 million US market and strengthens its North American generics portfolio, adding a new revenue stream. Authorized generics typically come with lower margins than branded drugs, so gains in volume and market share will be the key drivers of value for shareholders.